CTLA4 and neoplasm: CTLA-4 antibodies enhance anti-tumor activity by suppressing Treg activity or reducing the number of Tregs in the tumor tissue via antibody-dependent cellular cytotoxicity (ADCC) due to CTLA-4 overexpression on Tregs [71-73].